UNSPSC 51435000: Combination calcium channel blockers

This classification denotes combination drugs that act by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools, hence the term calcium channel blockers. Typical combination calcium channel blocker constituents are amlodipine and sodium chloride.

UNSPSC 51435000 Combination calcium channel blockers, a Class code, addresses state and local procurement of pharmaceuticals—specifically calcium channel blockers and related advanced life support medications—for emergency medical services, health plans, and institutional healthcare delivery. State and local governments buy these medications through competitive sealed bids, RFPs, and cooperative purchasing agreements, typically in quantities measured in hundreds to thousands of units annually. Issuing bodies span municipal fire and rescue services, state health and human services agencies, and multistate cooperative purchasing alliances. The scope encompasses not only the active pharmaceutical ingredient but also compliance with Good Manufacturing Practices, FDA registration, Safety Data Sheets under OSHA Hazard Communication Standards, Section 508 accessibility documentation, and expiration-date warranties—reflecting the regulated, mission-critical nature of emergency medication supply chains.

Recent activity shows concentration in Florida and the upper Midwest, with activity spanning both emergency medical service procurement and broader state pharmacy benefit programs. The City of Tampa, Florida issued IFB 26P00188 in April 2026 for Advanced Life Support Medications including Diltiazem 25mg vials and other cardiac agents, with response deadline April 8, 2026 and an estimated contract value of $40,000.00 under a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 exploring direct-to-manufacturer prescription programs that would include branded and generic pharmaceuticals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 with response deadline March 26, 2026 to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026 and performance penalties ranging from $200 to $1,500 per violation.